Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Diabetologia
Erschienen in: Diabetologia 3/2004

01.03.2004 | For Debate

Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications

verfasst von: M. Y. Donath, P. A. Halban

Erschienen in: Diabetologia | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Increasing evidence indicates that decreased functional beta-cell mass is the hallmark of both Type 1 and Type 2 diabetes. This underlies the absolute or relative insulin insufficiency in both conditions. In this For Debate, we consider the possible mechanisms responsible for beta-cell death and impaired function and their relative contribution to insulin insufficiency in diabetes. Beta-cell apoptosis and impaired proliferation consequent to hyperglycaemia is one pathway that could be operating in all forms of diabetes. Autoimmunity and other routes to beta-cell death are also considered. Recognition of decreased functional beta-cell mass and its overlapping multifactorial aetiology in diabetic states, leads us to propose a unifying classification of diabetes.
Literatur
1.
Yalow RS, Berson SA (1960) Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immuno-assay technic. Diabetes 9:254–260CrossRefPubMed
2.
Karam JH, Grodsky G, Forsham PH (1963) Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 12:197–204CrossRefPubMed
3.
Cerasi E, Luft R (1967) Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol (Copenh) 55:330–345
4.
DeFronzo RA (1988) Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667–687CrossRefPubMed
5.
Maclean N, Ogilvie RF (1955) Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 4:367–376CrossRefPubMed
6.
Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU (1985) Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110–125PubMed
7.
Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45:85–96CrossRefPubMed
8.
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with Type 2 diabetes. Diabetes 52:102–110CrossRefPubMed
9.
Yoon KH, Ko SH, Cho JH et al. (2003) Selective beta-cell loss and alpha-cell expansion in patients with Type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300–2308CrossRefPubMed
10.
Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D (1987) Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30:698–702CrossRefPubMed
11.
Kahn SE, Halban PA (1997) Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725–1732CrossRefPubMed
12.
Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D, Jr. (1984) Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7:491–502CrossRefPubMed
13.
Porksen N (2002) Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes. Diabetes Nutr Metab 15:9–14PubMed
14.
Polonsky KS, Given BD, Hirsch LJ et al. (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231–1239CrossRefPubMed
15.
Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3–19CrossRefPubMed
16.
Porksen N (2002) The in vivo regulation of pulsatile insulin secretion. Diabetologia 45:3–20CrossRefPubMed
17.
Ward GM, Walters JM, Aitken PM, Best JD, Alford FP (1990) Effects of prolonged pulsatile hyperinsulinemia in humans. Enhancement of insulin sensitivity. Diabetes 39:501–507CrossRefPubMed
18.
19.
Bonner-Weir S (2000) Islet growth and development in the adult. J Mol Endocrinol 24:297–302CrossRefPubMed
20.
Verchere CB, D Alessio DA, Palmiter RD et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492–3496CrossRefPubMedPubMedCentral
21.
Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241–253CrossRefPubMed
22.
Janson J, Soeller WC, Roche PC et al. (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:7283–7288CrossRefPubMedPubMedCentral
23.
Westermark P (1996) Islet pathology of non-insulin-dependent diabetes mellitus (NIDDM). Diabet Med 13:S46–S48PubMed
24.
Eizirik DL, Mandrup-Poulsen T (2001) A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115–2133CrossRefPubMed
25.
Corbett J, Serup P, Bonner Weir S, Nielsen JH (1997) Beta-cell ontogeny: growth and death. Diabetologia 40 [Suppl 3]:B27–B32
26.
Donath MY, Storling J, Maedler K, Mandrup-Poulsen T (2003) Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81:455–470CrossRefPubMed
27.
Federici M, Hribal M, Perego L et al. (2001) High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50:1290–1301CrossRefPubMed
28.
Maedler K, Spinas GA, Lehmann R et al. (2001) Glucose induces beta-cell apoptosis via upregulation of the fas receptor in human islets. Diabetes 50:1683–1690CrossRefPubMed
29.
Efanova IB, Zaitsev SV, Zhivotovsky B et al. (1998) Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. JBC 273:33501–33507CrossRef
30.
Hoorens A, Van de Casteele M, Kloppel G, Pipeleers D (1996) Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program. JCI 98:1568–1574CrossRefPubMedPubMedCentral
31.
Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738–744CrossRefPubMed
32.
Chick WL, Like AA (1970) Studies in the diabetic mutant mouse. 3. Physiological factors associated with alterations in beta cell proliferation. Diabetologia 6:243–251CrossRefPubMed
33.
Lipsett M, Finegood DT (2002) Beta-cell neogenesis during prolonged hyperglycemia in rats. Diabetes 51:1834–1841CrossRefPubMed
34.
Paris M, Bernard-Kargar C, Berthault MF, Bouwens L, Ktorza A (2003) Specific and combined effects of insulin and glucose on functional pancreatic beta-cell mass in vivo in adult rats. Endocrinology 144:2717–2727CrossRefPubMed
35.
Harding HP, Ron D (2002) Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 51:S455–S461CrossRefPubMed
36.
Araki E, Oyadomari S, Mori M (2003) Endoplasmic reticulum stress and diabetes mellitus. Intern Med 42:7–14CrossRefPubMed
37.
Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, Takeuchi T (2003) Dominant negative pathogenesis by mutant proinsulin in the akita diabetic mouse. Diabetes 52:409–416CrossRefPubMed
38.
Halban PA, Kahn SE, Lernmark A, Rhodes CJ (2001) Gene and cell-replacement therapy in the treatment of type 1 diabetes: how high must the standards be set? Diabetes 50:2181–2191CrossRefPubMed
39.
Grill V, Bjorklund A (2001) Overstimulation and beta-cell function. Diabetes 50 [Suppl 1]:S122–124
40.
Ihara Y, Toyokuni S, Uchida K et al. (1999) Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927–932CrossRefPubMed
41.
Laybutt DR, Kaneto H, Hasenkamp W et al. (2002) Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to [beta]-cell survival during chronic hyperglycemia. Diabetes 51:413–423CrossRefPubMed
42.
Maedler K, Sergeev P, Ris F et al. (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. JCI 110:851–860CrossRefPubMedPubMedCentral
43.
Maedler K, Fontana A, Ris F et al. (2002) FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci USA 99:8236–8241CrossRefPubMedPubMedCentral
44.
Shimabukuro M, Zhou YT, Levi M, Unger RH (1998) Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 95:2498–2502CrossRefPubMedPubMedCentral
45.
Roehrich ME, Mooser V, Lenain V et al. (2003) Insulin-secreting beta-cell dysfunction induced by human lipoproteins. JBC 278:18368–18375CrossRef
46.
Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY (2001) Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 50:69–76CrossRefPubMed
47.
Unger RH, Orci L (2002) Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 1585:202–212CrossRefPubMed
48.
Poitout V, Robertson RP (2002) Minireview: Secondary beta-Cell Failure in Type 2 Diabetes-A Convergence of Glucotoxicity and Lipotoxicity. Endocrinology 143:339–342
49.
El-Assaad W, Buteau J, Peyot ML et al. (2003) Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144:4154–4163CrossRefPubMed
50.
Roduit R, Thorens B (1997) Inhibition of glucose-induced insulin secretion by long-term preexposure of pancreatic islets to leptin. FEBS Lett 415:179–182CrossRefPubMed
51.
Kieffer TJ, Habener JF (2000) The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 278:E1–E14PubMed
52.
Shimabukuro M, Wang MY, Zhou YT, Newgard CB, Unger RH (1998) Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci USA 95:9558–9561CrossRefPubMedPubMedCentral
53.
Kendall DM, Sutherland DE, Najarian JS, Goetz FC, Robertson RP (1990) Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 322:898–903CrossRefPubMed
54.
Bonner-Weir S, Trent DF, Weir GC (1983) Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71:1544–1553CrossRefPubMedPubMedCentral
55.
Weir GC, Leahy JL, Bonner-Weir S (1986) Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev 2:125–161CrossRefPubMed
56.
Kjems LL, Kirby BM, Welsh EM et al. (2001) Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50:2001–2012CrossRefPubMed
57.
Kaiser N, Corcos AP, Sarel I, Cerasi E (1991) Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. Endocrinology 129:2067–2076CrossRefPubMed
58.
Eizirik DL, Korbutt GS, Hellerstrom C (1992) Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J Clin Invest 90:1263–1268CrossRefPubMedPubMedCentral
59.
Leahy JL, Cooper HE, Deal DA, Weir GC (1986) Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest 77:908–915CrossRefPubMedPubMedCentral
60.
UK Prospective Diabetes Study Group (1995) UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258CrossRef
61.
Leahy JL, Bonner-Weir S, Weir BC (1988) Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 81:1407–1414CrossRefPubMedPubMedCentral
62.
Kahn SE, Bergman RN, Schwartz MW, Taborsky GJ Jr, Porte D Jr (1992) Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am J Physiol 262:E518–523PubMed
63.
Glaser B, Cerasi E (1999) Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1:67–74CrossRefPubMed
64.
Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK (2003) Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 52:1098–1103CrossRefPubMed
65.
Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. JBC 278:471–478CrossRef
66.
Drucker DJ (2003) Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17:161–171CrossRefPubMed
67.
Greenwood RH, Mahler RF, Hales CN (1976) Improvement in insulin secretion in diabetes after diazoxide. Lancet 1:444–447CrossRefPubMed
68.
Bjork E, Berne C, Karlsson FA (1998) Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide. Diabetes Care 21:427–430CrossRefPubMed
69.
Guldstrand M, Grill V, Bjorklund A, Lins PE, Adamson U (2002) Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 28:448–456PubMed
70.
Report of the expert committee on the diagnosis and classification of diabetes mellitus (2003) Diabetes Care 26 [Suppl 1]:S5–S20
71.
Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M (2000) Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 49:32–38CrossRefPubMed
72.
Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 23:1755–1760CrossRefPubMed
73.
Kibirige M, Metcalf B, Renuka R, Wilkin TJ (2003) Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 26:2865–2870CrossRefPubMed
74.
Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ (2003) Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26:2871–2875CrossRefPubMed
75.
Syed MA, Barinas-Mitchell E, Pietropaolo SL et al. (2002) Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutr Metab 15:68–83.PubMed
76.
Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248CrossRefPubMed
77.
Spranger J, Kroke A, Mohlig M et al. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812–817CrossRefPubMed
78.
Bellone M, Iezzi G, Rovere P et al. (1997) Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 159:5391–5399PubMed
79.
O’Brien BA, Harmon BV, Cameron DP, Allan DJ (1997) Apoptosis is the mode of beta-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes 46:750–757CrossRefPubMed
80.
81.
Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 44:914–922CrossRefPubMed
82.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Diabetes Care 20:1183–1197CrossRef
83.
Diabetes Prevention Program (DPP) Research Group (2002) The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 25:2165–2171CrossRef
84.
Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed
85.
Pan XR, Li GW, Hu YH et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544CrossRefPubMed
86.
Maedler K, Bucher P, Berney T, Spinas GA, Carr RD, Donath MY (2003) Differential effects of repaglinide, nateglinide and glibenclamide on apoptosis in human beta cells in vitro. Diabetologia 46 [Suppl 2]:A187 (Abstract)
87.
Alvarsson M, Sundkvist G, Lager I et al. (2003) Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26:2231–2237CrossRefPubMed
Metadaten
Titel
Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications
verfasst von
M. Y. Donath
P. A. Halban
Publikationsdatum
01.03.2004
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 3/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1336-4

Weitere Artikel der Ausgabe 3/2004

Diabetologia 3/2004 Zur Ausgabe

Article

The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children

Short Communication

Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes

Review

Incretins, insulin secretion and Type 2 diabetes mellitus

Article

Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus

Article

Neointimal proliferation within carotid stents is more pronounced in diabetic patients with initial poor glycaemic state

Article

Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise